RESUMEN
Objective To investigate the efficacy and safety of cerebrolysin in patients with acute cerebral infarction(ACI).Methods A randomized,open-label,controlled trial ofcerebrolysin in the treatment of ACI within 48 h of onset was performed; these 108 patients were randomly divided into treatment group(n=64)and control group(n=44); the control group was only given routine therapy and the treatment group was allocated 30 mg cerebrolysin for 14 d.Therapeutic effect was evaluated by the National Institutes of Health Stroke Scale(NIHSS)and the Bathal index(BI).The liver and renal function,levels of blood and urinary routine,and electrocardiogram(ECG)were detected.Results As compared with those in the control group,significant difference on scores of NIHSS and BI was noted in the treatment group the treatment group(P＜0.05).Conclusion Cerebrolysin is efficacious in the treatment of AIC due to the improvement of neurological deficits of the patients.
RESUMEN
<p><b>OBJECTIVE</b>To establish the method to detect the cellular immune response of enhanced hepatitis B vaccine and make verification preliminary.</p><p><b>METHODS</b>Immunized BALB/c mice with enhanced hepatitis B vaccine and detected the IFN-gamma spots forming cells (SFC) of mouse spleen cell by Elispot. Optimized the conditions of the experiment. Cellular immune response between enhanced hepatitis B vaccine and normal hepatitis B vaccine by Elispot were compared.</p><p><b>RESULTS</b>IFN-gamma SFC was higher in 5microg dose than in 2microg dose after immunization with enhanced hepatitis B vaccine and IFN-gamma SFC was declined after immunization 3 weeks ago. IFN-gamma SFC was higher in stimulus by peptide than by protein. Compared to normal hepatitis B vaccine, IFN-gamma SFC was higher in enhanced hepatitis B vaccine.</p><p><b>CONCLUSION</b>Established the detection method to evaluate the cellular immunity of enhanced hepatitis B vaccine and tested the repeatability.</p>